April 25th 2025
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Dr Ryan Haumschild Discusses Payer, Provider Perspectives on Prior Authorization in Rare Diseases
September 19th 2023Ryan Haumschild, PharmD, MS, MBA, director of pharmacy at Emory Winship Cancer Institute, shares his unique perspectives as both a provider and payer on the use of prior authorizations (PAs) and "Gold Cards" in patients with rare diseases.
Watch
Dr Kristine Slam: Value-Based Care in Breast Cancer Requires Collaboration
September 19th 2023In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.
Watch
What We’re Reading: Mental Health AI Tools; Obesity Drug Shortages; Health Worker Mask Guidelines
September 18th 2023Artificial intelligence (AI) tools offer potential solutions to the growing demand in mental health; patients face weight loss drug shortages and insurance complications; updated mask guidelines cause worry among health care workers.
Read More
Regional Disparities Remain in Breast Reconstruction for Patients With Breast Cancer
September 15th 2023While regional variations were identified in rates of breast reconstruction, complications, and cost for patients with breast cancer, these differences did not seem to be associated with any implicit bias.
Read More
AAM Report: Generics and Biosimilars Generate $408 Billion in 2022
September 15th 2023A report from the Association for Accessible Medicines (AAM) highlighted the value of biosimilars and generics, revealing that lower-cost versions of originator products accumulated $408 billion for the US health care system in 2022.
Read More
Dr Andre Harvin: Specialty Pharmacists Are Integral to Oncology Care
September 10th 2023Specialty pharmacy is a big area of growth, with opportunity for patients, and specialty pharmacists can help payers and insurers ensure that patients get the full value of oncology medications, noted Andre Harvin, PharmD, MS, MBA, chief pharmacy officer, Oncology Services, Cone Health Cancer Centers.
Watch
Exploring Patient Spending in an ACO-Sponsored Care Management Program: A Case Study
September 8th 2023The authors’ multidisciplinary care management program shows promise, as the reduction in per-patient per-month spending was $116. However, these financial benefits took time to materialize.
Read More
National Alliance Guideline Identifies Key PBM Concerns for Health Plan Purchasers
September 7th 2023The playbook includes resources for purchasers to help in their dealings with pharmacy benefit managers (PBMs), including best practice checklists, sample questionnaires for choosing consultants, and recommendations for contracting language.
Read More
Dr G. B. John Mancini on Payer System Differences Between the US and Canada
September 7th 2023Care quality is high in both the United States and Canada, but there are commonalities in regard to drug access and cost issues, particularly with advanced medications, noted G. B. John Mancini, MD, University of British Columbia.
Watch
What We’re Reading: Worker Heat Safety; COVID-19 Anxiety; Nursing Home Staffing Rule
September 5th 2023Rising temperatures demand action against heat-related illnesses; school superintendents face complex decisions as COVID-19 cases rise; national staffing standards for nursing homes present challenges.
Read More
Laura Wingate: Biosimilars Can Improve Access to Treatment for Patients
September 3rd 2023Biosimilars can improve access to treatment for patients who might not have been able to access biologics previously, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Watch
Cost Analysis of Self-Monitoring Blood Glucose in Nonintensively Managed Type 2 Diabetes
Analysis of claims data showed reduced utilization and costs among patients with nonintensively managed type 2 diabetes using self-monitoring of blood glucose compared with continuous glucose monitoring.
Read More
Stelara and Enbrel Chosen for IRA Price Negotiation
August 31st 2023The Biden administration has released the first 10 drugs subject to price negotiation with Medicare under the Inflation Reduction Act (IRA), and among those chosen were Stelara (ustekinumab) and Enbrel (etanercept), both of which will face biosimilar competition within the next decade.
Read More